Table 4.
Proportions of plasma EPA and DHA after treatment, stratified by ELOVL2 rs2236212 genotype
| Treatment | n (GG/GC + CC)a | EPA | DHA | ||||
|---|---|---|---|---|---|---|---|
| GG | GC + CC | P* | GG | GC + CC | P* | ||
| Placebo | 23/42 | 0.98 (0.84,1.11) | 0.98 (0.88,1.08) | 0.727 | 2.22 (2.08,2.36) | 2.23 (2.13,2.34) | 0.553 |
| 0.45 g/day | 18/50 | 2.04 (1.67,2.42) | 1.76 (1.54,1.99) | 0.410 | 3.05 (2.82,3.28) | 2.82 (2.69,2.96) | 0.027 |
| 0.90 g/day | 29/49 | 2.52 (2.26,2.78) | 2.27 (2.08,2.46) | 0.131 | 3.36 (3.17,3.55) | 3.34 (3.20,3.48) | 0.281 |
| 1.80 g/day | 23/47 | 3.34 (2.88,3.80) | 4.20 (3.88,4.52) | 0.002 | 3.89 (3.67,4.11) | 4.24 (4.08,4.39) | 0.013 |
Data show mean (95 % CI) follow-up values for EPA and DHA as a percentage of total fatty acids, adjusted for baseline. Subjects received supplements of EPA and DHA (1.51:1) at the daily doses shown for 6 month
EPA eicosapentaenoic acid; DHA docosahexaenoic acid
* Significance of genotype association with proportions of fatty acids with respect to SNP genotype based on a dominant model was tested by multivariate ANOVA. Interaction between genotype and treatment was a significant determinant of EPA (P < 0.0001) and DHA (P = 0.004). All P-values were adjusted for baseline values, BMI, age, gender and ethnicity
a n = number of subjects in genotype groups GG and GC + CC